Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influence of Antacids on Raltegravir Pharmacokinetics in HIV
NCT02473367Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2015
- Primary completion
- Aug 2015
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of raltegravir in human immunodeficiency virus infection (HIV), sponsored by Merck & Co. Primary endpoints: Area Under the Plasma Concentration Time Curve From Time 0 to 24 Hrs, Maximum Plasma Concentration and 1 more. Started Jun 2015; status: completed.
02
Drugs
raltegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02473367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02473367.